Cytotoxic factor in the serum of diabetic rats and its increase during pregnancy.
Diabetic pregnancy is associated with a high incidence of fetal growth abnormalities which cannot be solely ascribed to fetal hyperglycaemia and hyperinsulinaemia. We therefore examined the possibility of other contributing factors using rats made diabetic with streptozotocin as the experimental model. Blood serum from virgin diabetic rats and, to a much greater extent, from pregnant diabetic rats inhibited [3H]thymidine incorporation by fetal lung cells in culture in a concentration- and time-dependent manner; cell number was also decreased. The cytotoxic activity of the serum was decreased by treatment of pregnant diabetic rats with insulin. Sera from non-diabetic rats and from rats at 6 h and 24 h after the injection of streptozotocin were not cytotoxic. The cytotoxic activity of diabetic rat serum was retained after dialysis and was not destroyed by heating it for 60 min at 60 degrees C. Diabetic rat serum antagonized the stimulatory effects of fetal bovine serum, insulin and insulin-like growth factors on thymidine incorporation by lung cells and inhibited corticosterone production by adrenal cells. Ultrafiltration of diabetic rat serum and high-performance gel permeation chromatography in phosphate buffer suggested that the molecular weight of the cytotoxic factor was approximately 40 kDa. However, gel permeation chromatography in 40% acetonitrile of the cytotoxic eluate from reversed-phase high-performance liquid chromatography using a C18 and C4 column revealed that the cytotoxic factor was a low molecular weight substance, which contained no amino acids. The apparent discrepancy in molecular weights using different separation procedures suggests that the cytotoxic factor is bound to serum proteins. The u.v. spectrum of this factor was different from those of ketone bodies but its exact chemical identity could not be established because of the scarcity of the material. It is suggested that the sera of pregnant diabetic rats and their fetuses contain a cytotoxic factor, which may contribute to fetal developmental abnormalities.
Conliffe
P R
PR
Endocrine Laboratory, Royal Victoria Hospital, Montreal, Quebec, Canada.
Santos
G L
GL
Varma
D R
DR
Mulay
S
S
D000311:Adrenal Glands / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D001685:Biological Factors / Q000097:blood*; D002452:Cell Count; D002478:Cells, Cultured; D002850:Chromatography, Gel; D002851:Chromatography, High Pressure Liquid; D000013:Congenital Abnormalities / Q000097:blood / Q000209:etiology*; D003345:Corticosterone / Q000096:biosynthesis; D003921:Diabetes Mellitus, Experimental / Q000097:blood*; D003956:Dialysis; D004305:Dose-Response Relationship, Drug; D005260:Female; D007329:Insulin Antagonists; D008168:Lung / Q000196:embryology / Q000378:metabolism; D008970:Molecular Weight; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood / Q000209:etiology*; D011254:Pregnancy in Diabetics / Q000097:blood*; D051381:Rats; D013002:Somatomedins / Q000037:antagonists & inhibitors; D013936:Thymidine / Q000378:metabolism
D001685:Biological Factors; D007329:Insulin Antagonists; D013002:Somatomedins; D013936:Thymidine; D003345:Corticosterone